Invivyd grants 157,500 options: what it means for Invivyd stock

Published on 10/06/2026 at 08:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LIBERTY cut six-day events to 56.50 percent versus 91.40 percent with vaccine. Invivyd stock awaits October safety data from DECLARATION.

IVVD, US00534A1025, Illustration mit AI erstellt.

Invivyd (ISIN US00534A1025) granted options covering 157,500 shares to six newly hired employees on October 1, 2026. The award adds a measurable dilution issue as the company prepares for another clinical readout, while Invivyd stock remains tied to the progress of its antibody pipeline.

What the options mean for dilution

According to GlobeNewswire on October 5, 2026, the options carry an exercise price of USD 0.82 per share and a 10-year term. They vest over four years, with 25.00 percent vesting after the first year and the remainder in equal monthly installments.

The grant is small relative to the companys broader equity base, but it gives investors a concrete reference point for employee compensation. On Nasdaq, IVVD was last at USD 0.84 on October 5, 2026 at 4:00 p.m. ET, versus a previous close of USD 0.82. The 52-week range was USD 0.53 to USD 3.07, while market capitalization stood at USD 247.2 million.

LIBERTY results sharpen the pipeline case

The larger catalyst is VYD2311, Invivyds investigational monoclonal antibody for COVID-19 prevention. In its September 29, 2026 release, Invivyd reported that 56.50 percent of participants receiving VYD2311 experienced a six-day overall safety event, compared with 91.40 percent for an mRNA-based vaccine.

The comparison extended beyond the first week. Over 56 days, the overall event rate was 60.90 percent with VYD2311 versus 91.40 percent with the vaccine, and systemic events over six days were 44.10 percent versus 68.10 percent. The trial enrolled 210 healthy adults, creating a quantified safety signal but not yet an efficacy result.

Revenue grows as losses remain high

Invivyds commercial base is developing alongside the clinical program. StockTitan reported that second-quarter 2026 net product revenue reached USD 14.3 million, up 21.00 percent from USD 11.8 million in the year-earlier quarter. The same filing summary placed the second-quarter 2026 net loss at USD 44.4 million, compared with USD 14.7 million a year earlier.

That contrast defines the investment case: product revenue is expanding, but the company continues to spend heavily to advance VYD2311 and prepare for regulatory work. The September release said Invivyd intends to pursue a Biologics License Application through the Accelerated Approval Program if the DECLARATION results support the plan.

October data are the next test

Invivyd expects DECLARATION safety and immunogenicity data in October 2026. The trial is planned as a confirmatory Phase 3 study with approximately 2,400 participants, so its safety and antibody data would carry greater weight than the 210-person LIBERTY study.

For investors, the central trade-off is visible in the numbers: LIBERTY showed a 30.50 percentage point gap in six-day overall events, while second-quarter net loss widened to USD 44.4 million. The employee option grant adds 157,500 shares to that developing risk and reward profile.

Nasdaq price and company profile

Invivyds primary listing is Nasdaq under ticker IVVD. The company develops antibody-based medicines for viral diseases, with VYD2311 and PEMGARDA central to its current pipeline and commercial activity.